Tony Schwartz, PhD
Long/short equity, growth, biotech

Celator: A Unique Drug Ratio Technology Company For Cancer

Company Overview

Celator Pharmaceuticals (NASDAQ:CPXX) is a clinical stage biopharmaceutical company developing novel formulations of currently approved drugs to treat various cancers. Their delivery platform, CombiPlex, consists of a nano-scale system that combines previously approved chemotherapy agents administered in fixed synergistic ratios. Combining drugs in fixed ratios maximizes the therapeutic response of each drug while maintaining the desired safety profile which is difficult to achieve using current combinational regimens. It allows for prolonged exposure to the drugs without increased toxic effects. CPX-351, Celator's lead formulation, consists of FDA approved Cytarabine and Daunorubicin (1:5 ratio) and is currently in a Phase 3 trial in Acute Myeloid Leukemia (AML). A positive Phase 3 trial can be achieved by demonstrating only...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details